Perindopril Related Compound 7 - CAS 80875-98-5


Perindopril Related Compound 7 is a chemically defined derivative associated with the widely studied ACE inhibitor perindopril. Its unique structure provides valuable insights into the metabolic pathways and degradation profiles involved in perindopril biosynthesis and transformation. Frequently used as a reference standard in analytical and stability studies, this compound aids in elucidating impurity profiles and reaction mechanisms. Perindopril Related Compound 7 is integral to pharmaceutical research and quality control development within drug synthesis workflows.

Product Information

Canonical SMILES
C1CCC2C(C1)CC(N2)C(=O)O
InChI
InChI=1S/C9H15NO2/c11-9(12)8-5-6-3-1-2-4-7(6)10-8/h6-8,10H,1-5H2,(H,11,12)/t6-,7-,8-/m0/s1
InChI Key
CQYBNXGHMBNGCG-FXQIFTODSA-N
Purity
≥ 98% (HPLC)
MDL
MFCD07782125
Appearance
White off-white solid
Storage
Store at 2-8 °C
Boiling Point
318.6°C at 760 mmHg
Melting Point
259-260 °C
Density
1.135 g/cm3
Optical Activity
-50 to -46 (c=1 in methanol)
Solubility
Soluble in Methanol, Water
TSCA
No

Safety Information

Signal Word
Warning
Precautionary Statement
P264b - P271 - P280 - P302+P352 - P304+P340 - P305+P351+P338 - P312 - P332+P313 - P362 - P501c - X
Hazard Statements
H315 - H319 - H335

Reference Reading

1.Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models.
Nagata S1, Takeyama K, Fukuya F, Nagai R, Hosoki K, Nishimura K, Deguchi T, Karasawa T. Arzneimittelforschung. 1995 Aug;45(8):853-8.
The antihypertensive properties of a new long-acting, angiotensin-I-converting enzyme (ACE) inhibiting agent, (2S,3aS,7aS)-1-(N2-nicotinoyl-L-lysyl-gamma-D-glutamyl) octahydro-1H-indole-2-carboxylic acid (CAS 116662-73-8, DU-1777), were investigated orally in various experimental models of hypertension in comparison to a standard ACE inhibitor, lisinopril. The hypotensive potency of DU-1777 was not as marked as that of lisinopril in renin-dependent hypertensive models, i.e., two-kidney one-clip renal hypertensive rats (2K-1C RHR) (ED-20mmHg: 3.1 versus 1.0 mg/kg) or two-kidney two-clip renal hypertensive dogs (2K-2C RHD) (ED-20 mmHg: 2.5 versus 1.0 mg/kg), though the actions of the two drugs were both long-lasting and dose-related. When spontaneously hypertensive rats (SHR) were used, however, DU-1777 was as active as lisinopril (ED-20 mmHg: 17.9 versus 13.6 mg/kg). The most distinguishing results with DU-1777 were its hypotensive effects in renin-independent hypertensive models.
2.Possible involvement of ATP-dependent K-channel related mechanisms in the antihypertensive and cough suppressant effects of the novel ACE inhibitor (2S, 3aS, 7aS)-1-(N2-nicotinoyl-L-lysyl-gamma-D-glutamyl)octahydro-1H- indole-2-carboxylic acid.
Nagata S1, Takeyama K, Hosoki K, Karasawa T. Arzneimittelforschung. 1997 Jun;47(6):726-30.
The antihypertensive and cough suppressant mechanisms of DU-1777 ((2S,3aS,7aS)-1-(N2-nicotinoyl-L-lsyl-gamma-D-glutamyl )octahydro-1H-indole-2 -carboxylic acid, CAS 116662-73-8), a new long-acting angiotensin-1-converting enzyme (ACE) inhibitor, were investigated in vivo and in vitro. The antihypertensive effects of DU-1777 at 10 mg/kg p.o. and cromakalim at 0.3 mg/kg p.o. were partially (about 60%) or fully antagonized by glibenclamide at 10 mg/kg i.v. in 2-kidney, 1-clip renal hypertensive rats (2K-1C RHR). The antihypertensive effects of a Ca blocker (nifedipine) and other ACE inhibitors (captopril, alacepril, enalapril, lisinopril, imidapril and quanapril) were not antagonized by glibenclamide. In deoxycorticosterone acetate-salt hypertensive rats (DOCA-HR), the antihypertensive effects of DU-1777 at 3-30 mg/kg p.o. were fully antagonized by glibenclamide. However, in vitro, DU-1777 (10(-6)-10(-3) mol/l) did not affect aortic ring contractions induced by high K (30 mmol/l).
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Online Inquiry
  • Verification code
USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
Germany
Copyright © 2026 BOC Sciences. All rights reserved.
Inquiry Basket
Top